|
Jan 31
|
Green Cross Health (NZSE:GXH) shareholders notch a 18% CAGR over 3 years, yet earnings have been shrinking
|
|
Jan 23
|
European Medicines Agency (EMA) Grants Orphan Drug Designation (ODD) to GC Biopharma's Treatment for Sanfilippo Syndrome (Type A)
|
|
Jan 8
|
GC Cell's Promising AB-201 Cancer Treatment to Begin Phase 1 Trials Using Lunit AI Platform
|
|
Jan 3
|
Declining Stock and Decent Financials: Is The Market Wrong About Green Cross Health Limited (NZSE:GXH)?
|
|
Dec 6
|
GC Biopharma's groundbreaking for the plasma fractionation plant in Indonesia
|
|
Dec 3
|
Green Cross Health's (NZSE:GXH) Dividend Is Being Reduced To NZ$0.0294
|
|
Dec 2
|
Income Investors Should Know That Green Cross Health Limited (NZSE:GXH) Goes Ex-Dividend Soon
|
|
Dec 1
|
GC Biopharma establishes mRNA production facility in Hwasun, Korea
|
|
Nov 6
|
The World's First "Recombinant Anthrax Vaccine": GC Biopharma applies for MFDS Approval
|
|
Aug 12
|
With 37% ownership, Green Cross Health Limited (NZSE:GXH) insiders have a lot riding on the company's future
|